BRPI0418623A - composição farmacêutica, e, embalagem - Google Patents

composição farmacêutica, e, embalagem

Info

Publication number
BRPI0418623A
BRPI0418623A BRPI0418623-0A BRPI0418623A BRPI0418623A BR PI0418623 A BRPI0418623 A BR PI0418623A BR PI0418623 A BRPI0418623 A BR PI0418623A BR PI0418623 A BRPI0418623 A BR PI0418623A
Authority
BR
Brazil
Prior art keywords
compositions
packaging
pharmaceutical composition
vaginitis
bioadhesive
Prior art date
Application number
BRPI0418623-0A
Other languages
English (en)
Inventor
Koral Embil
Gul Baktir
Ray Figueroa
Original Assignee
Edko Trading Representation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edko Trading Representation filed Critical Edko Trading Representation
Publication of BRPI0418623A publication Critical patent/BRPI0418623A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSIçãO FARMACêUTICA, E, EMBALAGEM. A invenção fornece composições farmacéuticas para a administração tópica no tratamento de infecções vaginais, por exemplo, vaginite. Tais composições compreendem: W pelo menos um composto de triazol ativo contra Candida albicans, preferivelmente pelo menos um tal composto que é adicionalmente ativo contra uma ou mais espécies de Candida que não a albicans, e (ii) pelo menos um medicamento anti-vaginite adicional, preferivelmente um agente antifúngico, antiprotozoário e/ou antibacteriano. As composições preferidas incluem como agentes ativos o terconazol em combinação com tinidazol e/ou tioconazol. Em um outro aspecto as composições de acordo com a invenção também incluem um agente bioadesivo, por exemplo, um mucoadesivo, para promover a adesão à mucosa vaginal. O uso de um bioadesivo também pode fornecer a liberação controlada, por exemplo, rápida e/ou demorada (prolongada), dos agentes ativos.
BRPI0418623-0A 2004-03-10 2004-09-17 composição farmacêutica, e, embalagem BRPI0418623A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0405406.0A GB0405406D0 (en) 2004-03-10 2004-03-10 Anti-vaginitis compositions
PCT/GB2004/003972 WO2005087270A1 (en) 2004-03-10 2004-09-17 Anti-vaginitis compositions comprising a triazole

Publications (1)

Publication Number Publication Date
BRPI0418623A true BRPI0418623A (pt) 2007-05-29

Family

ID=32117416

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0418623-0A BRPI0418623A (pt) 2004-03-10 2004-09-17 composição farmacêutica, e, embalagem

Country Status (7)

Country Link
CN (1) CN1960763A (pt)
BR (1) BRPI0418623A (pt)
EA (1) EA011952B1 (pt)
GB (1) GB0405406D0 (pt)
PL (1) PL380815A1 (pt)
TR (1) TR200606411T1 (pt)
WO (1) WO2005087270A1 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4167964A4 (en) * 2020-06-18 2024-07-17 Nat Medical Supply Llc VAGINAL GEL

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060140990A1 (en) * 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
WO2005027807A1 (en) 2003-09-19 2005-03-31 Drugtech Corporation Pharmaceutical delivery system
MX2008001687A (es) * 2005-08-12 2008-02-19 Drugtech Corp Composiciones de estrogenos y metodos terapeuticos de uso.
JP2009522360A (ja) * 2006-01-05 2009-06-11 ドラッグテック コーポレイション 組成物およびその使用方法
EA200870155A1 (ru) * 2006-01-05 2009-02-27 Драгтек Корпорейшн Система доставки лекарственного средства
US9211286B2 (en) * 2006-09-12 2015-12-15 Curatek Pharmaceuticals Holding, Inc. Terconazole composition and method
US10758630B2 (en) 2010-08-13 2020-09-01 The Johns Hopkins University Topical compositions and methods of detection and treatment
IT1403661B1 (it) 2011-01-28 2013-10-31 Probiotical Spa Composizione effervescente in forma solida per uso in applicazioni vaginali per il trattamento di infezioni vaginali.
CN102091097B (zh) * 2011-01-28 2013-04-03 武汉耦合医学科技有限责任公司 一种免冲洗产妇会阴医疗护理凝胶及其制备方法
ITMI20110792A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia.
ITMI20110791A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri in grado di metabolizzare gli ossalati.
ITMI20111718A1 (it) 2011-09-23 2013-03-24 Probiotical Spa Un materiale impermeabile alla umidita e allo ossigeno per confezionare prodotti dietetici, cosmetici e specialita medicinali.
WO2014027006A1 (en) 2012-08-13 2014-02-20 Edko Pazarlama Tanitim Ticaret Limited Sirketi Bioadhesive formulations for use in drug delivery
WO2014026707A1 (en) 2012-08-13 2014-02-20 Edko Pazarlama Tanitim Ticaret Limited Sirketi Anti-vaginitis compositions with improved release and adherence
ITMI20130793A1 (it) 2013-05-14 2014-11-15 Probiotical Spa Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle cistiti ricorrenti.
CA2916002A1 (en) * 2013-06-25 2014-12-31 Mission Pharmacal Company Novel formulations for the treatment of vaginal disorders
MX2018002533A (es) 2015-09-29 2018-06-27 Kimberly Clark Co Composicion sinergica para el mantenimiento de un equilibrio saludable de la microflora.
BR112019015239A2 (pt) 2017-02-28 2020-04-14 Kimberly Clark Co composição, e, método para manter um equilíbrio de microflora saudável na área urogenital de um paciente com necessidade do mesmo.
WO2021154188A1 (en) * 2020-01-31 2021-08-05 Exeltis Ilac Sanayii Ve Ticaret Anonim Sirketi Pharmaceutical composition suitable for vaginal delivery
CN111759840B (zh) * 2020-07-20 2021-05-11 温州市人民医院 一种防治心肌缺血的药物组合物及其制备方法和用途
CN112190541A (zh) * 2020-09-27 2021-01-08 安婕妤化妆品科技股份有限公司 一种私密护理凝胶产品
CN112245657B (zh) * 2020-10-19 2022-07-01 合肥中科智远生物科技有限公司 一种低放热抗菌骨水泥及其制备方法与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663208A (en) * 1991-03-01 1997-09-02 Warner-Lambert Company Antifungal wound healing compositions and methods for preparing and using same
ATE199215T1 (de) * 1993-12-23 2001-03-15 Procter & Gamble Antimikrobielle zusammensetzungen für abwischtücher
GB9610359D0 (en) * 1996-05-17 1996-07-24 Edko Trading Representation Pharmaceutical compositions
US20030073646A1 (en) * 1997-01-22 2003-04-17 Marton Milankovits Pharmaceutical compositions primarily for the treatment of genitourinary infections
US6416779B1 (en) * 1997-06-11 2002-07-09 Umd, Inc. Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections
FR2777783A1 (fr) * 1998-04-24 1999-10-29 Innothera Lab Sa Association pharmaceutique d'imidazoles pour le traitement local des vulvo-vaginites infectieuses et des vaginoses

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4167964A4 (en) * 2020-06-18 2024-07-17 Nat Medical Supply Llc VAGINAL GEL

Also Published As

Publication number Publication date
PL380815A1 (pl) 2007-03-19
GB0405406D0 (en) 2004-04-21
EA200601647A1 (ru) 2007-02-27
EA011952B1 (ru) 2009-06-30
CN1960763A (zh) 2007-05-09
TR200606411T1 (tr) 2007-01-22
WO2005087270A1 (en) 2005-09-22

Similar Documents

Publication Publication Date Title
BRPI0418623A (pt) composição farmacêutica, e, embalagem
BRPI0615860B8 (pt) composição farmacêutica de liberação prolongada monolítica sólida
AR050838A1 (es) Formulacion farmaceutica. para el tratamiento de una infeccion optica
WO2003086408A8 (en) Use of a2a adenosine receptor agonists for the treatment of inflammatory diseases
AR030068A1 (es) Composiciones farmaceuticas para el tratamiento de condiciones dolorosas, inflamatorias y ulcerosas de superficies epiteliales humedas como por ejemplo mucositis, estomatitis y sindrome de behcet
ATE293995T1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
PT1401501E (pt) Composicoes farmaceuticas orais com libertacao modificada do ingrediente activo
BR9808581A (pt) Estabilização de benzimidazóis sensìveis a ácido com combinações de aminoácido/ciclodextrina
WO2003020219A3 (en) Aerosolized decongestants for the treatment of sinusitis
MX2009005307A (es) Nuevas composiciones bajo la forma de ungüento libre de vaselina, que comprenden un derivado de vitamina d y eventualmente un anti-inflamatorio esteroide.
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
WO2007131253A3 (de) Verwendung von kombinationspräparaten, umfassend antimykotika
BR0210595A (pt) Regime de dosagem e composição farmacêutica para contracepção de emergência
CO5580787A2 (es) Metodos novedosos para el tratamiento de infecciones micoticas y bacterianas locales
MX2023002671A (es) Formulaciones agradables.
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
BRPI0414305A (pt) sistema de liberação de drogas por via oral
BR0309057A (pt) Formulações lìquidas com baixa dosagem em entecavir e uso
DK1414467T3 (da) Topisk behandling af mastalgi
MA33563B1 (fr) 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl
AR036357A1 (es) Composicion de gel endoparasiticida, un metodo para su preparacion y el uso de dicha composición para la manufactura de un medicamento.
HRP20090022T3 (en) Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superfinfections and fungal recurrences
NO20073575L (no) Farmasoytiske sammensetninger for behandling av cellulitt
CA2417935A1 (en) Anti-inflammatory medicament
BR0209155A (pt) Tablete farmacêutico tendo um teor de api elevado

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B25D Requested change of name of applicant approved

Owner name: EDKO PAZARLAMA TANITIM LIMITED SIRKETI (TR)

Free format text: NOME ALTERADO DE: EDKO TRADING AND REPRESENTATION CO. LTD.

B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 9A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.